Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

Table 2 Correlations between expression of receptors for BAFF and expression of markers for B and plasma cells, type I IFN production and plasmacytoid dendritic cells in muscle tissue ^a

	BAFF-R^b	BCMA^b	TACI^b	CD19^b	CD138^b
	(n=15)	(n=15)	(n=15)	(n=12)	(n=12)
CD19^b	0.49^†	0.44^†	0.19
(n =12)	0.49^†	0.44^†	0.19
CD138^b	0.70**	0.79***	0.39	0.39
(n =12)	0.70**	0.79***	0.39	0.39
MX-1^c	0.23	0.33	0.38^†	0.12	−0.01
(n =15)	0.23	0.33	0.38^†	0.12	−0.01
BDCA-2^c	0.16	0.42^†	0.23	0.37	0.54*
(n =15)	0.16	0.42^†	0.23	0.37	0.54*

^aBAFF-R, B-cell-activating factor of the tumour necrosis factor family receptor; BCMA, B-cell maturation antigen; BDCA-2, Blood dendritic cell antigen 2; MX-1, Interferon α/β–inducible myxovirus resistance 1 protein; TACI, Transmembrane activator and calcium modulator and cyclophilin ligand interactor. Data included to correlation analysis were: ^bNumbers of positive cells counted by conventional microscopy per area (n/mm²). Included samples which expressed at least one of the receptors. ^cQuantitative evaluation of expression by computerised image analysis (percentage of positively stained area). Data are correlation coefficients of Spearman’s rank order test. ***P <0.005, **P <0.01, *P <0.05, ^†P <0.1.

ISSN: 1478-6362